title: Using the cost-effectiveness of allogeneic islet transplantation to inform induced pluripotent stem cell-derived β-cell therapy reimbursement.
abstract: OBJECTIVE
  In the present study a cost-effectiveness analysis of allogeneic islet transplantation was performed and the financial feasibility of a human induced pluripotent stem cell-derived β-cell therapy was explored.
  
  
  METHODS
  Previously published cost and health benefit data for islet transplantation were utilized to perform the cost-effectiveness and sensitivity analyses.
  
  
  CONCLUSIONS
  It was determined that, over a 9-year time horizon, islet transplantation would become cost saving and 'dominate' the comparator. Over a 20-year time horizon, islet transplantation would incur significant cost savings over the comparator (GB£59,000). Finally, assuming a similar cost of goods to islet transplantation and a lack of requirement for immunosuppression, a human induced pluripotent stem cell-derived β-cell therapy would dominate the comparator over an 8-year time horizon.
authors.affiliation: Centre for Biological Engineering, Loughborough University, Loughborough, UK.
authors.forename: Peter R T
authors.initials: PR
authors.lastname: Archibald
authors.affiliation: Centre for Biological Engineering, Loughborough University, Loughborough, UK.
authors.forename: David J
authors.initials: DJ
authors.lastname: Williams
mesh_terms: D064591:Allografts; D003365:Costs and Cost Analysis; D005260:Female; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000637:transplantation*; D050417:Insulin-Secreting Cells / Q000637:transplantation*; D016381:Islets of Langerhans Transplantation / Q000191:economics* / Q000379:methods; D008297:Male; D006113:United Kingdom
keywords: allogeneic islet transplantation; cost–effectiveness; diabetes; incremental cost–effectiveness ratio; induced pluripotent stem cell; quality-adjusted life years; reimbursement; β cell